These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

590 related articles for article (PubMed ID: 28923561)

  • 1. Update on the Safety of Phosphodiesterase Type 5 Inhibitors for the Treatment of Erectile Dysfunction.
    Yafi FA; Sharlip ID; Becher EF
    Sex Med Rev; 2018 Apr; 6(2):242-252. PubMed ID: 28923561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The safety of phosphodiesterase type 5 inhibitors for erectile dysfunction.
    Ventimiglia E; Capogrosso P; Montorsi F; Salonia A
    Expert Opin Drug Saf; 2016; 15(2):141-52. PubMed ID: 26752541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phosphodiesterase 5 inhibitors for the treatment of erectile dysfunction: a trade-off network meta-analysis.
    Chen L; Staubli SE; Schneider MP; Kessels AG; Ivic S; Bachmann LM; Kessler TM
    Eur Urol; 2015 Oct; 68(4):674-80. PubMed ID: 25817916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphodiesterase Type-5 Inhibitor Prescription Patterns in the United States Among Men With Erectile Dysfunction: An Update.
    Mulhall JP; Chopra I; Patel D; Hassan TA; Tang WY
    J Sex Med; 2020 May; 17(5):941-948. PubMed ID: 32144034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erectile function recovery in men treated with phosphodiesterase type 5 inhibitor administration after bilateral nerve-sparing radical prostatectomy: a systematic review of placebo-controlled randomized trials with trial sequential analysis.
    Limoncin E; Gravina GL; Corona G; Maggi M; Ciocca G; Lenzi A; Jannini EA
    Andrology; 2017 Sep; 5(5):863-872. PubMed ID: 28787547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphodiesterases 5 Inhibitors and Erectile Dysfunction Recovery after Pelvic Surgery: Future Perspectives for New Drugs and New Formulations.
    Lombardo R; Tema G; De Nunzio C
    Curr Drug Targets; 2021; 22(1):31-37. PubMed ID: 32981502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative efficacy and safety of phosphodiesterase type 5 inhibitors for erectile dysfunction in diabetic men: a Bayesian network meta-analysis of randomized controlled trials.
    Liao X; Qiu S; Bao Y; Wang W; Yang L; Wei Q
    World J Urol; 2019 Jun; 37(6):1061-1074. PubMed ID: 30523399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic Review of Oral Combination Therapy for Erectile Dysfunction When Phosphodiesterase Type 5 Inhibitor Monotherapy Fails.
    Munk NE; Knudsen JS; Comerma-Steffensen S; Simonsen U
    Sex Med Rev; 2019 Jul; 7(3):430-441. PubMed ID: 30711478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of Melanoma With Phosphodiesterase Type 5 Inhibitor Use Among Patients With Erectile Dysfunction, Pulmonary Hypertension, and Lower Urinary Tract Symptoms.
    Shkolyar E; Li S; Tang J; Eisenberg ML
    J Sex Med; 2018 Jul; 15(7):982-989. PubMed ID: 29884444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Avanafil - a further step to tailoring patient needs and expectations.
    Boeri L; Capogrosso P; Ventimiglia E; Serino A; La Croce G; Russo A; Damiano R; Montorsi F; Salonia A
    Expert Rev Clin Pharmacol; 2016 Sep; 9(9):1171-81. PubMed ID: 27232892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative efficacy of tadalafil once daily in men with erectile dysfunction who demonstrated previous partial responses to as-needed sildenafil, tadalafil, or vardenafil.
    Kim E; Seftel A; Goldfischer E; Baygani S; Burns P
    Curr Med Res Opin; 2015 Feb; 31(2):379-89. PubMed ID: 25455432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk-benefit assessment of oral phosphodiesterase type 5 inhibitors for treatment of erectile dysfunction: a multiple criteria decision analysis.
    Hsu JC; Tang DH; Lu CY
    Int J Clin Pract; 2015 Apr; 69(4):436-43. PubMed ID: 25311239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medical treatment of erectile dysfunction: too many medical prescriptions?
    Capogrosso P; Ventimiglia E; Oreggia D; Salonia A; Montorsi F
    Urologia; 2017 Aug; 84(3):121-129. PubMed ID: 28708203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral phosphodiesterase type 5 inhibitors and male reproductive potential: an overview.
    Mostafa T; Alghobary M; Hanafy NS; Abosief A
    Sex Med Rev; 2023 Jun; 11(3):240-252. PubMed ID: 36990971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic review and meta-analysis of phosphodiesterase type 5 inhibitors for the treatment of female sexual dysfunction.
    Gao L; Yang L; Qian S; Li T; Han P; Yuan J
    Int J Gynaecol Obstet; 2016 May; 133(2):139-45. PubMed ID: 26797204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recreational Use of Oral PDE5 Inhibitors: The Other Side of Midnight.
    Mostafa T; Alghobary MF
    Sex Med Rev; 2022 Jul; 10(3):392-402. PubMed ID: 34903486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The "Kiel Concept" of Long-Term Administration of Daily Low-Dose Sildenafil Initiated in the Immediate Post-Prostatectomy Period: Evaluation and Comparison With the International Literature on Penile Rehabilitation.
    Osmonov DK; Jünemann KP; Bannowsky A
    Sex Med Rev; 2017 Jul; 5(3):387-392. PubMed ID: 28372960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An update on the drug safety of treating erectile dysfunction.
    Gul M; Serefoglu EC
    Expert Opin Drug Saf; 2019 Oct; 18(10):965-975. PubMed ID: 31433252
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of Genetic Polymorphism on the Response to PDE5 Inhibitors in Patients With Erectile Dysfunction: A Systematic Review and a Critical Appraisal.
    Mostafa T; Hassan A; Alghobary MF; Abdelrahman SH
    Sex Med Rev; 2020 Oct; 8(4):573-585. PubMed ID: 32636154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety profile and signal detection of phosphodiesterase type 5 inhibitors for erectile dysfunction: a Food and Drug Administration Adverse Event Reporting System analysis.
    Shin YE; Rojanasarot S; Hincapie AL; Guo JJ
    Sex Med; 2023 Oct; 11(5):qfad059. PubMed ID: 38034088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.